Oligonucleotide pharmacology and formulation: G3139 anti-BCL2 phosphorothioate in stealth® liposomes and gel implants

Nucleosides and Nucleotides

Volumn 16, Issue 7-9, 1997, Pages 1731-1734

  Woodle, M C ^a   Raynaud, F I ^b   Dizik, M ^a   Meyer, O ^c   Huang, S K ^d   Jaeger, J A ^a   Brown, B D ^a   Orr, R ^b   Judson, I R ^b   Papahadjopoulos, D ^c  

^a Genta Inc   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GRAFT; CONFERENCE PAPER; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FORMULATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PROTEIN SYNTHESIS REGULATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALIA;

EID: 9844266789     PISSN: 07328311     EISSN: None     Source Type: Journal    
DOI: 10.1080/07328319708006265     Document Type: Conference Paper

References (5)

1. Srinivasan, S.K. & Iversen, P. (1995) J. Clin. Lab. Anal. 9, 129-137.
2. Cotter, F.E., Johnson, P., Hall, P. & Pocock, C. (1994) Oncogene 9, 3049-3055.
3. Webb, A., Cunningham, D., Cotter, F., Hill, M., Clarke, P., di Stefano, F., Viner, C., Prendeville, J., Rahal, S., Dziewanowska, Z. (1996) Annals Oncology 7 (Supplement 3), Abstract 101.
4. Lebedev, A.V., Raynaud, F., Dizik, M., Beck, T.A., Jaeger, J.A., Brown, B.D., Cunningham, D., Webb, A., McCampbell, E., Riley, T., Judson, I. & Woodle, M.C. (1996) Nucleosides and Nucleotides, this issue.
5. Woodle, M.C. (1995) Adv. Drug Del. Rev. 16, 249-265.